Clinical data | |
---|---|
Pronunciation | /ɛɡzˈɛnətaɪd/ |
Trade names | Byetta, Bydureon, Bydureon BCise, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a605034 |
License data | |
Pregnancy category |
|
Routes of administration | Subcutaneous injection |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | N/A |
Metabolism | proteolysis |
Elimination half-life | 2.4 h |
Excretion | Kidney/proteolysis |
Chemical and physical data | |
Formula | C184H282N50O60S |
Molar mass | 4186.63 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Exenatide, sold under the brand name Byetta and Bydureon among others, is a medication used to treat diabetes mellitus type 2.[2] It is used together with diet, exercise, and potentially other antidiabetic medication.[2] It is a less preferred treatment option after metformin and sulfonylureas.[3] It is given by injection under the skin within an hour before the first and last meal of the day.[2] A once-weekly injection version is also available.[2]
Common side effects include low blood sugar, nausea, dizziness, abdominal pain, and pain at the site of injection.[2] Other serious side effects may include medullary thyroid cancer, angioedema, pancreatitis, and kidney injury.[2] Use in pregnancy and breastfeeding is of unclear safety.[4] Exenatide is a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) also known as incretin mimetics.[2] It works by increasing insulin release from the pancreas and decreases excessive glucagon release.[2]
Exenatide was approved for medical use in the United States in 2005.[2] A month supply in the United Kingdom costs the NHS about £82 for the daily injectable and £73 for the weekly injectable version as of 2019.[3] In the United States the wholesale cost of this amount is about US$700 and US$789 respectively.[5] In 2017, it was the 260th most commonly prescribed medication in the United States, with more than one million prescriptions.[6][7]
References edit
- ^ a b Cite error: The named reference
WHO2020DDD
was invoked but never defined (see the help page). - ^ a b c d e f g h i "Exenatide Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 22 March 2019.
- ^ a b British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 684–685. ISBN 9780857113382.
- ^ "Exenatide Pregnancy and Breastfeeding Warnings". Drugs.com. Retrieved 3 March 2019.
- ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.
- ^ "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
- ^ "Exenatide - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.